Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
The HICCC is the home for cancer research and patient care at Columbia University and NewYork-Presbyterian/Columbia University Irving Medical Center. Their cancer center researchers and physicians are dedicated to understanding the complex biology behind cancer, from before it begins to its evolution and spread. The HICCC is one of only 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States, a designation maintained since 1979.
“Our innovative cancer therapies and prevention strategies can help reduce cancer’s incidence and progression and improve the quality of life for all those affected,” said Dr. Anil Rustgi, Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center. “We look forward to working with the POA’s network in research as we remain committed to our mission to reducing the burden of cancer for our patients, our community and the world.”
“We are thrilled that the HICCC joined the POA. As a leader in innovation and discovery in cancer research, HICCC complements the mission of the POA,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “Their vision to design new ways to look at cancer biology, understand how it evolves, and develop novel and precise therapies that halt its progress align with Caris’ vision to provide the best treatment options to patients worldwide that would ultimately improve their outcomes and their quality of life.”
“The HICCC has maintained its status as a top cancer center in the United States for more than 40 years by offering an exceptional environment of patient care and biomedical research,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “The POA is excited to welcome their knowledge of innovative cancer care and research to further precision medicine and cancer treatments across the globe.”
The Caris Precision Oncology Alliance includes 57 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1,000,000 data points per patient.
People In This Post
Companies In This Post
- Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Read more
- Celyad Oncology Appoints Georges Rawadi as Its New CEO Read more
- Companion Spine Closes $60.1 Million Series A Funding Round Read more
- EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Read more
- Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer Read more